Somewhat Favorable News Coverage Somewhat Unlikely to Impact Theravance Biopharma (TBPH) Share Price

Headlines about Theravance Biopharma (NASDAQ:TBPH) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Theravance Biopharma earned a news impact score of 0.22 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.0772949542175 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have effected Accern’s rankings:

Shares of Theravance Biopharma (NASDAQ:TBPH) opened at $28.14 on Wednesday. The company has a market cap of $1,520.00, a P/E ratio of -5.45 and a beta of 2.09. Theravance Biopharma has a 52-week low of $22.90 and a 52-week high of $43.44. The company has a current ratio of 7.53, a quick ratio of 7.21 and a debt-to-equity ratio of 1.21.

A number of analysts have weighed in on TBPH shares. Needham & Company LLC reissued a “buy” rating on shares of Theravance Biopharma in a research report on Tuesday, December 5th. ValuEngine downgraded shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Cantor Fitzgerald reissued a “buy” rating and set a $55.00 target price on shares of Theravance Biopharma in a research report on Tuesday, November 7th. BidaskClub raised shares of Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 20th. Finally, Robert W. Baird reaffirmed a “sell” rating and set a $22.00 price objective on shares of Theravance Biopharma in a research report on Wednesday, November 1st. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Theravance Biopharma presently has an average rating of “Hold” and a consensus price target of $42.00.

COPYRIGHT VIOLATION WARNING: This article was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Insider Buying and Selling by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply